Infliximab biosimilar - Biocad

Drug Profile

Infliximab biosimilar - Biocad

Alternative Names: BCD-055

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocad
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Antiulcers
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Rheumatoid arthritis

Most Recent Events

  • 13 Jun 2018 Efficacy and adverse events data from the phase III ASART-2 trial in Ankylosing spondylitis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 13 Jun 2018 Efficacy, adverse events and immunogenicity data from the phase III LIRA trial in Rheumatoid arthritis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Ankylosing-spondylitis in Belarus (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top